Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli

The research team at Centrum Onkologii Ziemi Lubelskiej is conducting a series of studies on cancers of the gastrointestinal tract, aiming to improve survival and quality of life by testing novel targeted agents, immunotherapies, and diagnostic tools.

• Advanced gastric and gastro‑esophageal junction adenocarcinoma
• Esophageal squamous cell carcinoma
• Unresectable hepatocellular carcinoma
• Metastatic BRCA‑mutated pancreatic cancer
• Combination regimens with checkpoint inhibitors for digestive cancers

These trials bring together more than thirty investigators to evaluate new treatment options for patients across Lublin and the broader region.

A robust portfolio of hematology studies focuses on B‑cell malignancies and related disorders, with the goal of establishing more effective and tolerable therapies for both newly diagnosed and relapsed patients.

• Chronic lymphocytic leukemia / small lymphocytic lymphoma
• Mantle cell lymphoma and other aggressive B‑cell lymphomas
• Diffuse large B‑cell lymphoma, including high‑risk subgroups
• Multiple myeloma, including relapsed/refractory disease
• Acute myeloid leukemia with NPM1 mutation

Investigators are exploring BTK inhibitors, bispecific antibodies, and CAR‑T cell approaches to deepen responses and reduce disease burden.

Clinical research at the site includes pioneering work on immune‑modulating therapies, ranging from checkpoint blockade to gene‑engineered cellular products, to enhance anti‑tumor immunity and address primary immunodeficiencies.

• Gene‑modified T‑cell therapy safety and long‑term efficacy
• PD‑1/PD‑L1 inhibitors such as pembrolizumab and durvalumab
• Combination immunotherapy with axitinib or tiragolumab
• Primary immunodeficiency disease diagnostics using advanced imaging
• Evaluation of novel immune checkpoint combinations in solid tumours

The programme seeks to define optimal regimens that balance potency with safety for patients with complex immune‑related conditions.

A wide‑ranging oncology portfolio addresses major solid tumours, aiming to compare new targeted agents and combination strategies against standard chemotherapy to improve progression‑free and overall survival.

• Hormone‑receptor‑positive, HER2‑negative early and advanced breast cancer
• HER2‑positive metastatic breast cancer and neoadjuvant settings
• Ovarian cancer, including BRCA‑mutated and platinum‑sensitive disease
• Prostate cancer with advanced or metastatic disease
• Metastatic melanoma and head & neck squamous cell carcinoma

Through collaborations with international sponsors, the centre evaluates CDK4/6 inhibitors, antibody‑drug conjugates, and novel hormone therapies to set new standards of care.

Targeted investigations into cutaneous malignancies and related disorders are underway, focusing on innovative immunotherapies and precision medicines to improve outcomes for patients with skin‑derived cancers.

• Advanced melanoma, including brain‑metastatic cohorts
• Cutaneous T‑cell lymphoma and other skin‑related lymphoid neoplasms
• Evaluation of checkpoint inhibitors in skin cancer subtypes
• Biomarker‑driven studies for connective‑tissue tumor profiling
• Safety assessment of combination regimens involving targeted agents

The department leverages its expertise in dermatologic oncology to generate data that may translate into more personalized treatment pathways.